Loyola University Medical Center

Gottlieb Memorial Hospital

MacNeal Hospital

Back to homepage
myLoyola

Jeanine M Walenga, PhD

Clinical Pathology

Primary Contact

888-584-7888
Accepting New Patients
Primary Contact
888-584-7888
Print Share

Services & Specialties

Areas of Specialization

  • Clinical Pathology

Locations & Contact

Primary Location

Loyola University Medical Center

2160 S First Ave
Maywood, IL 60153

View hours
Sunday
Open 24 hours
Monday
Open 24 hours
Tuesday
Open 24 hours
Wednesday
Open 24 hours
Thursday
Open 24 hours
Friday
Open 24 hours
Saturday
Open 24 hours
Loyola University Medical Center
888-584-7888 View Details

Education & Certifications

Education

Education:
University Deparis Sorbonne (1987)

Publications

  • Erratum: Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus Paper. Harenberg, J.; Gosselin, R. C.; Cuker, A.; Becattini, C.; Pabinger, I.; Poli, S.; Weitz, J.; Ageno, W.; Bauersachs, R.; Celap, I.; Choi, P.; Douketis, J.; Douxfils, J.; Elalamy, I.; Falanga, A.; Fareed, J.; Favaloro, E. J.; Gerotziafas, G.; Herkner, H.; Hetjens, S.; Heubner, L.; Klamroth, R.; Langer, F.; Lip, G. Y. H.; Mac Grory, B.; Margetić, S.; Merrelaar, A.; Pikta, M.; Renne, T.; Schulman, S.; Schwameis, M.; Strbian, D.; Tafur, A.; Vassart, J.; Violi, F.; Walenga, J.; Weiss, C.; Thrombosis and haemostasis
  • The DOAC (direct oral anticoagulant) Dipstick reliably excludes residual FXa inhibitors levels in the preoperative setting. Vassart, J.; Tafur, A.; Durante, M.; Boucher, A. Y.; Morimont, L.; Walenga, J. M.; Harenberg, J.; Douxfils, J.; Thrombosis research
  • Prevention and management of venous thromboembolism. International Consensus Statement. Guidelines according to scientific evidence. Nicolaides, A. N.; Fareed, J.; Spyropoulos, A. C.; Kakkar, R. H. L.; Antignani, P. L.; Avgerinos, E.; Baekgaard, N.; Barber, E.; Bush, R. L.; Caprini, J. A.; Clarke-Pearson, D. L.; VAN Dreden, P.; Elalami, I.; Gerotziafas, G.; Gibbs, H.; Goldhaber, S.; Kakkos, S.; Lefkou, E.; Labropoulos, N.; Lopes, R. D.; Mansilha, A.; Papageorgiou, C.; Prandoni, P.; Ramacciotti, E.; Rognoni, C.; Urbanek, T.; Walenga, J. M.; International angiology : a journal of the International Union of Angiology
  • Algorithm for Rapid Exclusion of Clinically Relevant Plasma Levels of Direct Oral Anticoagulants in Patients Using the DOAC Dipstick: An Expert Consensus Paper. Harenberg, J.; Gosselin, R. C.; Cuker, A.; Becattini, C.; Pabinger, I.; Poli, S.; Weitz, J.; Ageno, W.; Bauersachs, R.; Celap, I.; Choi, P.; Douketis, J.; Douxfils, J.; Elalamy, I.; Falanga, A.; Fareed, J.; Favaloro, E. J.; Gerotziafas, G.; Herkner, H.; Hetjens, S.; Heubner, L.; Klamroth, R.; Langer, F.; Lip, G. Y. H.; Mac Grory, B.; Margetić, S.; Merrelaar, A.; Pikta, M.; Renne, T.; Schulman, S.; Schwameis, M.; Strbian, D.; Tafur, A.; Vassart, J.; Violi, F.; Walenga, J.; Weiss, C.; Thrombosis and haemostasis
  • Association of Angiopoetin-2 and TNF-α With Bleeding During Left Ventricular Assist Device Support: Analysis From the PREVENT Biorepository. Kim, G.; Sayer, G.; Ransom, J.; Keebler, M.; Katz, J.; Kilic, A.; Lindenfeld, J.; Egnaczyk, G.; Shah, P.; Brieke, A.; Walenga, J.; Crandall, D.; Farrar, D. J.; Sundareswaran, K.; Uriel, N.; ASAIO journal (American Society for Artificial Internal Organs : 1992)
  • Glycemic Control and Plasma Levels of Pro-Inflammatory and Pro-Thrombotic Biomarkers in Diabetic Patients Presenting with Acute Pulmonary Embolism. O'Hara, A.; Pozin, J.; Darki, A.; Siddiqui, F.; Hoppensteadt, D.; Walenga, J.; Fareed, J.; Kantarcioglu, B.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Enhanced Thrombin Formation in Patients With Ventricular Assist Devices Experiencing Bleeding: Insights From the Multicenter PREVENT Study. Jeske, W.; Ransom, J.; Katz, J. N.; Kilic, A.; Lindenfeld, J.; Egnaczyk, G.; Shah, P.; Brieke, A.; Uriel, N.; Crandall, D.; Farrar, D. J.; Walenga, J. M.; ASAIO journal (American Society for Artificial Internal Organs : 1992)
  • Inflammatory cytokines in robot-assisted thoracic surgery versus video-assisted thoracic surgery. Jaradeh, M.; Curran, B.; Poulikidis, K.; Rodrigues, A.; Jeske, W.; Abdelsattar, Z. M.; Lubawski, J.; Walenga, J.; Vigneswaran, W. T.; Journal of thoracic disease
  • Predictive Role of Blood Cellular Indices and Their Relationship with Endogenous Glycosaminoglycans as Determinants of Inflammatory Biomarkers in Pulmonary Embolism. Kantarcioglu, B.; Darki, A.; Siddiqui, F.; Krupa, E.; Vural, M.; Kacmaz, M.; Hoppensteadt, D.; Iqbal, O.; Jeske, W.; Walenga, J.; Adiguzel, C.; Fareed, J.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Multiplex genome editing of mammalian cells for producing recombinant heparin. Thacker, B. E.; Thorne, K. J.; Cartwright, C.; Park, J.; Glass, K.; Chea, A.; Kellman, B. P.; Lewis, N. E.; Wang, Z.; Di Nardo, A.; Sharfstein, S. T.; Jeske, W.; Walenga, J.; Hogwood, J.; Gray, E.; Mulloy, B.; Esko, J. D.; Glass, C. A.; Metabolic engineering
  • An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination. Kantarcioglu, B.; Iqbal, O.; Walenga, J. M.; Lewis, B.; Lewis, J.; Carter, C. A.; Singh, M.; Lievano, F.; Tafur, A.; Ramacciotti, E.; Gerotziafas, G. T.; Jeske, W.; Fareed, J.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Angiopoietin-2 correlates with pulmonary embolism severity, right ventricular dysfunction, and intensive care unit admission. Newman, J.; Brailovsky, Y.; Allen, S.; Bontekoe, E.; Masic, D.; Walenga, J.; Fareed, J.; Darki, A.; Vascular medicine (London, England)
  • Protein C Pathway, Inflammation, and Pump Thrombosis in Patients With Left Ventricular Assist Devices. Walenga, J. M.; Torres, T. A.; Jeske, W. P.; Schwartz, J.; Escalante, V.; Newman, J. D.; Bakhos, M.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Heparin: Much more than anti-IIa/anti-Xa. Walenga, J. M.; Journal de medecine vasculaire
  • Zika and Chikungunya Virus and Risk for Venous Thromboembolism. Ramacciotti, E.; Agati, L. B.; Aguiar, V. C. R.; Wolosker, N.; Guerra, J. C.; de Almeida, R. P.; Alves, J. C.; Lopes, R. D.; Wakefield, T. W.; Comerota, A. J.; Walenga, J.; Fareed, J.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Bovine Mucosal Heparins Are Comparable to Porcine Mucosal Heparin at USP Potency Adjusted Levels. Jeske, W.; Kouta, A.; Farooqui, A.; Siddiqui, F.; Rangnekar, V.; Niverthi, M.; Laddu, R.; Hoppensteadt, D.; Iqbal, O.; Walenga, J.; Fareed, J.; Frontiers in medicine
  • Profiling Heparin-Induced Thrombocytopenia (HIT) Antibodies in Hospitalized Patients With and Without Diabetes. Prechel, M.; Hudec, S.; Lowden, E.; Escalante, V.; Emanuele, N.; Emanuele, M.; Walenga, J. M.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Medical management of stable peripheral artery disease: the COMPASS trial. Perspectives from a vascular standpoint. Ramacciotti, E.; Castelli, V.; Walenga, J.; Fareed, J.; International angiology : a journal of the International Union of Angiology
  • Identification of Novel Hemostatic Biomarkers of Adverse Clinical Events in Patients Implanted With a Continuous-Flow Left Ventricular Assist Device. McClane, N.; Jeske, W.; Walenga, J. M.; Escalante, V.; Hoppensteadt, D.; Schwartz, J.; Bakhos, M.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Sulodexide for the extended treatment of venous thromboembolism. Walenga, J. M.; Fareed, J.; Ramacciotti, E.; International angiology : a journal of the International Union of Angiology
  • Blood cell microparticles as biomarkers of hemostatic abnormalities in patients with implanted cardiac assist devices. Jeske, W. P.; Walenga, J. M.; Menapace, B.; Schwartz, J.; Bakhos, M.; Biomarkers in medicine
  • North American Thrombosis Forum, AF Action Initiative Consensus Document. Ruff, C. T.; Ansell, J. E.; Becker, R. C.; Benjamin, E. J.; Deicicchi, D. J.; Mark Estes, N. A.; Ezekowitz, M. D.; Fanikos, J.; Fareed, J.; Garcia, D.; Giugliano, R. P.; Goldhaber, S. Z.; Granger, C.; Healey, J. S.; Hull, R.; Hylek, E. M.; Libby, P.; Lopes, R. D.; Mahaffey, K. W.; Mega, J.; Piazza, G.; Sasahara, A. A.; Sorond, F. A.; Spyropoulos, A. C.; Walenga, J. M.; Weitz, J. I.; The American journal of medicine
  • Complexes of platelet factor 4 and heparin activate Toll-like receptor 4. Prechel, M. M.; Walenga, J. M.; Journal of thrombosis and haemostasis : JTH
  • Sustained release of tissue factor following thrombosis of lower limb trauma. Walenga, J. M.; Kaiser, P. C.; Prechel, M. M.; Hoppensteadt, D.; Jeske, W. P.; Misselwitz, F.; Bacher, P.; Lassen, M. R.; Fareed, J.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Production of Anti-platelet Factor 4/Heparin Complex Antibodies After Cardiovascular Surgery. Matsuo, T.; Motohashi, S.; Wanaka, K.; Walenga, J. M.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer. Walenga, J. M.; Lyman, G. H.; Critical reviews in oncology/hematology
  • Increase in cardiac myosin binding protein-C plasma levels is a sensitive and cardiac-specific biomarker of myocardial infarction. Govindan, S.; Kuster, D. W.; Lin, B.; Kahn, D. J.; Jeske, W. P.; Walenga, J. M.; Leya, F.; Hoppensteadt, D.; Fareed, J.; Sadayappan, S.; American journal of cardiovascular disease
  • Apixaban as an alternate oral anticoagulant for the management of patients with heparin-induced thrombocytopenia. Walenga, J. M.; Prechel, M.; Hoppensteadt, D.; Escalante, V.; Chaudhry, T.; Jeske, W. P.; Bakhos, M.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia. Prechel, M. M.; Walenga, J. M.; Thrombosis journal
  • Anticoagulant and Antithrombotic Actions of AVE5026, an Enriched Anti-Xa Hemisynthetic Ultra-Low-Molecular-Weight Heparin. Hoppensteadt, D. A.; Gray, A.; Jeske, W. P.; Walenga, J. M.; Fareed, J.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Left ventricular assist device-induced coagulation and platelet activation and effect of the current anticoagulant therapy regimen. Ashbrook, M.; Walenga, J. M.; Schwartz, J.; Heroux, A.; Jeske, W. P.; Escalante, V.; Bakhos, M.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Comparative studies on branded enoxaparin and a US generic version of enoxaparin. Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D.; Cunanan, J.; Khan, H.; Escalante, V.; Fareed, J.; Bakhos, M.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Nonhemostatic adverse effects of anticoagulants and antiplatelet agents. Walenga, J. M.; Thethi, I.; Lewis, B. E.; Seminars in thrombosis and hemostasis
  • Heparin-induced thrombocytopenia: an update. Prechel, M.; Walenga, J. M.; Seminars in thrombosis and hemostasis
  • A colorimetric, metabolic dye reduction assay detects highly activated platelets: application in the diagnosis of heparin-induced thrombocytopenia. Prechel, M. M.; Escalante, V.; Drenth, A. F.; Walenga, J. M.; Platelets
  • A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin. Jeske, W. P.; Hoppensteadt, D.; Gray, A.; Walenga, J. M.; Cunanan, J.; Myers, L.; Fareed, J.; Bayol, A.; Rigal, H.; Viskov, C.; Thrombosis research
  • Low molecular weight heparins differ substantially: impact on developing biosimilar drugs. Walenga, J. M.; Jackson, C. M.; Kessler, C. M.; Seminars in thrombosis and hemostasis
  • Functionality of fondaparinux (pentasaccharide) depends on clinical antithrombin levels. Jeske, W. P.; Walenga, J. M.; Samama, M. M.; Hoppensteadt, D.; Mayuga, M.; Fareed, J.; Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  • An open label, non-randomized, prospective clinical trial evaluating the immunogenicity of branded enoxaparin versus biosimilars in healthy volunteers. Gomes, M.; Ramacciotti, E.; Hoppensteadt, D.; Walenga, J. M.; Lewis, B.; Thethi, I.; Fareed, J.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Pharmacology of argatroban. Jeske, W. P.; Fareed, J.; Hoppensteadt, D. A.; Lewis, B.; Walenga, J. M.; Expert review of hematology
  • Laboratory methods and management of patients with heparin-induced thrombocytopenia. Prechel, M.; Jeske, W. P.; Walenga, J. M.; Methods in molecular biology (Clifton, N.J.)
  • Drug and dietary interactions of the new and emerging oral anticoagulants. Walenga, J. M.; Adiguzel, C.; International journal of clinical practice
  • In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative. Kuziej, J.; Litinas, E.; Hoppensteadt, D. A.; Liu, D.; Walenga, J. M.; Fareed, J.; Jeske, W.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Profiling of heparin-induced thrombocytopenia antibody levels in patients with and without diabetes. Diaz, J.; Prechel, M.; Emanuele, M.; Emanuele, N.; Walenga, J. M.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Physiological changes in membrane-expressed platelet factor 4: implications in heparin-induced thrombocytopenia. Prechel, M. M.; Jeske, W. P.; Walenga, J. M.; Thrombosis research
  • Comparative anticoagulant and platelet modulatory effects of enoxaparin and sulodexide. Adiguzel, C.; Iqbal, O.; Hoppensteadt, D.; Jeske, W.; Cunanan, J.; Litinas, E.; He Zhu; Walenga, J. M.; Fareed, J.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products. Adiguzel, C.; Jeske, W. P.; Hoppensteadt, D.; Walenga, J. M.; Bansal, V.; Fareed, J.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia. Walenga, J. M.; Prechel, M.; Jeske, W. P.; Hoppensteadt, D.; Maddineni, J.; Iqbal, O.; Messmore, H. L.; Bakhos, M.; British journal of haematology
  • Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effect on coagulation factor testing. Walenga, J. M.; Drenth, A. F.; Mayuga, M.; Hoppensteadt, D. A.; Prechel, M.; Harder, S.; Watanabe, H.; Osakabe, M.; Breddin, H. K.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update. Prechel, M.; Walenga, J. M.; Seminars in thrombosis and hemostasis
  • Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins. Jeske, W. P.; Walenga, J. M.; Hoppensteadt, D. A.; Vandenberg, C.; Brubaker, A.; Adiguzel, C.; Bakhos, M.; Fareed, J.; Seminars in thrombosis and hemostasis
  • The future of anticoagulation. Hoppensteadt, D. A.; Jeske, W.; Walenga, J.; Fareed, J.; Seminars in respiratory and critical care medicine
  • The relationship between the antiphospholipid syndrome and heparin-induced thrombocytopenia. Hoppensteadt, D. A.; Walenga, J. M.; Hematology/oncology clinics of North America
  • Inflammatory and hemostatic activation in patients undergoing off-pump coronary artery bypass grafting. Untch, B. R.; Jeske, W. P.; Schwartz, J.; Botkin, S.; Prechel, M.; Walenga, J. M.; Bakhos, M.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Non-anticoagulant effects of unfractionated and low-molecular weight heparins. Walenga, J. M.; Clinical advances in hematology & oncology : H&O
  • Heparin oligosaccharides as potential therapeutic agents in senile dementia. Ma, Q.; Cornelli, U.; Hanin, I.; Jeske, W. P.; Linhardt, R. J.; Walenga, J. M.; Fareed, J.; Lee, J. M.; Current pharmaceutical design
  • Isolation and characterization of heparin from tuna skins. Jeske, W. P.; McDonald, M. K.; Hoppensteadt, D. A.; Bau, E. C.; Mendes, A.; Dietrich, C. P.; Walenga, J. M.; Coyne, E.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications. Maddineni, J.; Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D. A.; Fareed, J.; Wahi, R.; Bick, R. L.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides. Ma, Q.; Tobu, M.; Schultz, C.; Jeske, W.; Hoppensteadt, D.; Walenga, J.; Cornelli, U.; Lee, J.; Linhardt, R.; Hanin, I.; Fareed, J.; Thrombosis research
  • Update on the clinical applications of argatroban. Fareed, J.; Jeske, W. P.; Hoppensteadt, D. A.; Walenga, J. M.; Future cardiology
  • Activation of platelets by heparin-induced thrombocytopenia antibodies in the serotonin release assay is not dependent on the presence of heparin. Prechel, M. M.; McDonald, M. K.; Jeske, W. P.; Messmore, H. L.; Walenga, J. M.; Journal of thrombosis and haemostasis : JTH
  • Unfractionated heparin compared with low-molecular-weight heparin as related to heparin-induced thrombocytopenia. Walenga, J. M.; Prechel, M.; Jeske, W. P.; Bakhos, M.; Current opinion in pulmonary medicine
  • Short- and long-acting synthetic pentasaccharides as antithrombotic agents. Walenga, J. M.; Jeske, W. P.; Fareed, J.; Expert opinion on investigational drugs
  • Pharmacology of argatroban. Jeske, W.; Walenga, J. M.; Lewis, B. E.; Fareed, J.; Expert opinion on investigational drugs
  • Emerging anticoagulant and thrombolytic drugs. Iqbal, O.; Aziz, S.; Hoppensteadt, D. A.; Ahmad, S.; Walenga, J. M.; Bakhos, M.; Fareed, J.; Expert opinion on emerging drugs
  • Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization. Iqbal, O.; Tobu, M.; Aziz, S.; Gerdisch, M.; Da Valle, M.; Demir, M.; Hoppensteadt, D. A.; Ahmad, S.; Walenga, J. M.; Fareed, J.; Journal of cardiac surgery
  • Development of generic low molecular weight heparins: a perspective. Fareed, J.; Leong, W.; Hoppensteadt, D. A.; Jeske, W. P.; Walenga, J.; Bick, R. L.; Hematology/oncology clinics of North America
  • Generic low-molecular-weight heparins: some practical considerations. Fareed, J.; Leong, W. L.; Hoppensteadt, D. A.; Jeske, W. P.; Walenga, J.; Wahi, R.; Bick, R. L.; Seminars in thrombosis and hemostasis
  • Monitoring the new antithrombotic drugs. Walenga, J. M.; Hoppensteadt, D. A.; Seminars in thrombosis and hemostasis
  • Decreased prevalence of heparin-induced thrombocytopenia with low-molecular-weight heparin and related drugs. Walenga, J. M.; Jeske, W. P.; Prechel, M. M.; Bacher, P.; Bakhos, M.; Seminars in thrombosis and hemostasis
  • Newer insights on the mechanism of heparin-induced thrombocytopenia. Walenga, J. M.; Jeske, W. P.; Prechel, M. M.; Bakhos, M.; Seminars in thrombosis and hemostasis
  • Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: implications in the HIT pathogenesis. Ahmad, S.; Untch, B.; Haas, S.; Hoppensteadt, D. A.; Misselwitz, F.; Messmore, H. L.; Walenga, J. M.; Fareed, J.; Molecular and cellular biochemistry
  • Factor Xa inhibitors. Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D.; Fareed, J.; Methods in molecular medicine
  • Laboratory methods for heparin-induced thrombocytopenia. Prechel, M.; Jeske, W. P.; Walenga, J. M.; Methods in molecular medicine
  • Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia. Jeske, W. P.; Walenga, J. M.; Methods in molecular medicine
  • Argatroban use during pediatric interventional cardiac catheterization. Cetta, F.; Graham, L. C.; Wrona, L. L.; Arruda, M. J.; Walenga, J. M.; Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
  • Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice. Fareed, J.; Hoppensteadt, D.; Walenga, J.; Iqbal, O.; Ma, Q.; Jeske, W.; Sheikh, T.; Clinical pharmacokinetics
  • Bleeding complications with glycoprotein IIb/IIIa inhibitors. Iqbal, O.; Walenga, J. M.; Lewis, B. E.; Bakhos, M.; Drugs of today (Barcelona, Spain : 1998)
  • Argatroban in HIT type II and acute coronary syndrome. Lewis, B. E.; Walenga, J. M.; Pathophysiology of haemostasis and thrombosis
  • An overview of the direct thrombin inhibitor argatroban. Walenga, J. M.; Pathophysiology of haemostasis and thrombosis
  • Factor Xa inhibitors: today and beyond. Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D.; Fareed, J.; Current opinion in investigational drugs (London, England : 2000)
  • Investigations of the immunoglobulin subtype transformation of anti-heparin-platelet factor 4 antibodies during treatment with a low-molecular-weight heparin (clivarin) in orthopedic patients. Ahmad, S.; Bacher, H. P.; Lassen, M. R.; Hoppensteadt, D. A.; Leitz, H.; Misselwitz, F.; Walenga, J. M.; Fareed, J.; Archives of pathology & laboratory medicine
  • Heparin-induced thrombocytopenia with associated thrombosis in children after the Fontan operation: report of two cases. Porcelli, R.; Moskowitz, B. C.; Cetta, F.; Graham, L. C.; Godwin, J. E.; Eidem, B. W.; Prechel, M. M.; Walenga, J. M.; Texas Heart Institute journal
  • Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation. Hoppensteadt, D.; Walenga, J. M.; Fareed, J.; Bick, R. L.; Hematology/oncology clinics of North America
  • Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other adverse effects of heparin-type therapy. Walenga, J. M.; Frenkel, E. P.; Bick, R. L.; Hematology/oncology clinics of North America
  • Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies. Ahmad, S.; Haas, S.; Hoppensteadt, D. A.; Lietz, H.; Reid, U.; Bender, N.; Messmore, H. L.; Misselwitz, F.; Bacher, P.; Gaikwad, B. S.; Jeske, W. P.; Walenga, J. M.; Fareed, J.; Thrombosis research
  • Monitoring of argatroban in ARG310 study: potential recommendations for its use in interventional cardiology. Iqbal, O.; Ahmad, S.; Lewis, B. E.; Walenga, J. M.; Rangel, Y.; Fareed, J.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia. Jeske, W. P.; Walenga, J. M.; Current opinion in investigational drugs (London, England : 2000)
  • Development of a non-human primate sub-clinical model of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodies. Untch, B.; Ahmad, S.; Messmore, H. L.; Schultz, C. L.; Ma, Q.; Hoppensteadt, D. A.; Walenga, J. M.; Fareed, J.; Thrombosis research
  • Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Walenga, J. M.; Ahmad, S.; Hoppensteadt, D.; Iqbal, O.; Hursting, M. J.; Lewis, B. E.; Thrombosis research
  • Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. The pathogenic role of IgG. Untch, B.; Ahmad, S.; Jeske, W. P.; Messmore, H. L.; Hoppensteadt, D. A.; Walenga, J. M.; Lietz, H.; Fareed, J.; Thrombosis research
  • Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Walenga, J. M.; Jeske, W. P.; Samama, M. M.; Frapaise, F. X.; Bick, R. L.; Fareed, J.; Expert opinion on investigational drugs
  • The hemostatic effects of warfarin titration in post CABG patients in comparison to placebo treatment. Walenga, J. M.; Hoppensteadt, D.; Pifarré, R.; Fox, N. L.; Forman, S.; Hunninghake, D. B.; Campeau, L.; Herd, J. A.; Hoogwerf, B. J.; Hickey, A.; Probstfield, J. L.; Terrin, M. L.; Journal of thrombosis and thrombolysis
  • Evaluation of a new point of care heparin test for cardiopulmonary bypass: the TAS heparin management test. Wallock, M.; Jeske, W. P.; Bakhos, M.; Walenga, J. M.; Perfusion
  • Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist. Ahmad, S.; Jeske, W. P.; Ma, Q.; Walenga, J. M.; Fareed, J.; Thrombosis research
  • Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Lewis, B. E.; Wallis, D. E.; Berkowitz, S. D.; Matthai, W. H.; Fareed, J.; Walenga, J. M.; Bartholomew, J.; Sham, R.; Lerner, R. G.; Zeigler, Z. R.; Rustagi, P. K.; Jang, I. K.; Rifkin, S. D.; Moran, J.; Hursting, M. J.; Kelton, J. G.; ARG-911 Study Investigators; Circulation
  • Synthetic heparin pentasaccharide depolymerization by heparinase I: molecular and biological implications. Daud, A. N.; Ahsan, A.; Iqbal, O.; Walenga, J. M.; Silver, P. J.; Ahmad, S.; Fareed, J.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • The impact of antithrombin (H) concentrate infusions on pulmonary function in the acute phase of thermal injury. Kowal-Vern, A.; Walenga, J. M.; McGill, V.; Gamelli, R. L.; Burns : journal of the International Society for Burn Injuries
  • Antithrombin(H) concentrate infusions are safe and effective in patients with thermal injuries. Kowal-Vern, A.; McGill, V.; Walenga, J. M.; Gamelli, R. L.; The Journal of burn care & rehabilitation
  • Mechanisms of venous and arterial thrombosis in heparin-induced thrombocytopenia. Walenga, J. M.; Jeske, W. P.; Messmore, H. L.; Journal of thrombosis and thrombolysis
  • Human anti-heparin-platelet factor 4 antibodies are capable of activating primate platelets: towards the development of a HIT model in primates. Ahmad, S.; Jeske, W. P.; Walenga, J. M.; Aldabbagh, A.; Iqbal, O.; Fareed, J.; Thrombosis research
  • Pharmacokinetics of argatroban in primates: evidence on endogenous uptake. Ahmad, S.; Yang, L. H.; Ahsan, A.; Fu, K.; Iqbal, O.; Hoppensteadt, D. A.; Lewis, B. E.; Walenga, J. M.; Fareed, J.; International angiology : a journal of the International Union of Angiology
  • Soluble P-selectin in human plasma: effect of anticoagulant matrix and its levels in patients with cardiovascular disorders. Amin, H. M.; Ahmad, S.; Walenga, J. M.; Hoppensteadt, D. A.; Leitz, H.; Fareed, J.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Vascular damage correlates between heparin-induced thrombocytopenia and the antiphospholipid syndrome. Walenga, J. M.; Michal, K.; Hoppensteadt, D.; Wood, J. J.; Robinson, J. A.; Bick, R. L.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Heparin-induced thrombocytopenic potential of GAG and non-GAG-based antithrombotic agents. Jeske, W. P.; Jay, A. M.; Haas, S.; Walenga, J. M.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Antithrombin agents: the new class of anticoagulant and antithrombotic drugs. Fareed, J.; Lewis, B. E.; Callas, D. D.; Hoppensteadt, D. A.; Walenga, J. M.; Bick, R. L.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Soluble adhesion molecules in the HIT syndrome: pathophysiologic role and therapeutic modulation. Fareed, J.; Walenga, J. M.; Hoppensteadt, D. A.; Jeske, W. P.; Ahmad, S.; Lietz, H.; McKenna, R.; Messmore, H. L.; Haas, S.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Functional heterogeneity of antiheparin-platelet factor 4 antibodies: implications in the pathogenesis of the HIT syndrome. Ahmad, S.; Walenga, J. M.; Jeske, W. P.; Cella, G.; Fareed, J.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Laboratory diagnosis of heparin-induced thrombocytopenia. Walenga, J. M.; Jeske, W. P.; Fasanella, A. R.; Wood, J. J.; Ahmad, S.; Bakhos, M.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Ahmad, S.; Jeske, W. P.; Walenga, J. M.; Hoppensteadt, D. A.; Wood, J. J.; Herbert, J. M.; Messmore, H. L.; Fareed, J.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Simultaneous monitoring of argatroban and its major metabolite using an HPLC method: potential clinical applications. Ahmad, S.; Ahsan, A.; George, M.; Iqbal, O.; Jeske, W. P.; McKenna, R.; Lewis, B. E.; Walenga, J. M.; Fareed, J.; Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • Clinical laboratory monitoring of a synthetic antithrombin agent, argatroban, using high performance liquid chromatography and functional methods. Ahmad, S.; Iqbal, O.; Ahsan, A.; Hoppensteadt, D. A.; Lewis, B. E.; Walenga, J. M.; Fareed, J.; International angiology : a journal of the International Union of Angiology
  • Antithrombin III concentrate in the acute phase of thermal injury. Kowal-Vern, A.; McGill, V.; Walenga, J. M.; Gamelli, R. L.; Burns : journal of the International Society for Burn Injuries
  • Laboratory monitoring of pentasaccharide in a dog model of hemodialysis. Hoppensteadt, D. A.; Jeske, W. P.; Walenga, J. M.; Fu, K.; Yang, L. H.; Ing, T. S.; Herbert, J. M.; Fareed, J.; Thrombosis research
  • Hemostatic effects of 1 mg daily warfarin on post CABG patients. Post CABG Studies Investigators. Walenga, J. M.; Hoppensteadt, D.; Pifarré, R.; Cressman, M. D.; Hunninghake, D. B.; Fox, N. L.; Terrin, M. L.; Probstfield, J. L.; Journal of thrombosis and thrombolysis
  • Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT. Walenga, J. M.; Jeske, W. P.; Wallis, D. E.; Bakhos, M.; Lewis, B. E.; Leya, F.; Fareed, J.; Seminars in thrombosis and hemostasis
  • Coagulation laboratory testing in patients treated with argatroban. Walenga, J. M.; Fasanella, A. R.; Iqbal, O.; Hoppensteadt, D. A.; Ahmad, S.; Wallis, D. E.; Bakhos, M.; Seminars in thrombosis and hemostasis
  • Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopenia. Izban, K. F.; Lietz, H. W.; Hoppensteadt, D. A.; Jeske, W. P.; Fareed, J.; Bakhos, M.; Walenga, J. M.; Seminars in thrombosis and hemostasis
  • Laboratory tests for the diagnosis of heparin-induced thrombocytopenia. Walenga, J. M.; Jeske, W. P.; Fasanella, A. R.; Wood, J. J.; Bakhos, M.; Seminars in thrombosis and hemostasis
  • Selectins in the HIT syndrome: pathophysiologic role and therapeutic modulation. Fareed, J.; Walenga, J. M.; Hoppensteadt, D. A.; Jeske, W. P.; Lietz, H.; Ahmad, S.; Callas, D.; Messmore, H. L.; Haas, S.; Seminars in thrombosis and hemostasis
  • Antithrombin agents as anticoagulants and antithrombotics: implications in drug development. Fareed, J.; Callas, D.; Hoppensteadt, D. A.; Lewis, B. E.; Bick, R. L.; Walenga, J. M.; Seminars in hematology
  • Laboratory tests for heparin-induced thrombocytopenia: a multicenter study. Walenga, J. M.; Jeske, W. P.; Wood, J. J.; Ahmad, S.; Lewis, B. E.; Bakhos, M.; Seminars in hematology
  • Low molecular weight heparins: are they different? Fareed, J.; Hoppensteadt, D.; Jeske, W.; Clarizio, R.; Walenga, J. M.; The Canadian journal of cardiology
  • Low-molecular-weight heparins: pharmacologic profile and product differentiation. Fareed, J.; Jeske, W.; Hoppensteadt, D.; Clarizio, R.; Walenga, J. M.; The American journal of cardiology
  • Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy. Walenga, J. M.; Bick, R. L.; The Medical clinics of North America
  • Antithrombin agents as anticoagulants and antithrombotics. Implications in drug development. Fareed, J.; Callas, D.; Hoppensteadt, D. A.; Walenga, J. M.; Bick, R. L.; The Medical clinics of North America
  • Molecular markers of hemostatic activation and inflammation following major injury: effect of therapy with IFN-gamma. Dries, D. J.; Walenga, J. M.; Hoppensteadt, D.; Fareed, J.; Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
  • Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets. Jeske, W. P.; Walenga, J. M.; Szatkowski, E.; Ero, M.; Herbert, J. M.; Haas, S.; Bakhos, M.; Thrombosis research
  • Trauma and thermal injury: comparison of hemostatic and cytokine changes in the acute phase of injury. Kowal-Vern, A.; Sharp-Pucci, M. M.; Walenga, J. M.; Dries, D. J.; Gamelli, R. L.; The Journal of trauma
  • Efficacy of pentasaccharide in a dog model of hemodialysis. Hoppensteadt, D. A.; Jeske, W. P.; Walenga, J. M.; Fu, K.; Yang, L. H.; Ing, T.; Herbert, J. M.; Fareed, J.; Thrombosis research
  • Current status on new anticoagulant and antithrombotic drugs and devices. Walenga, J. M.; Fareed, J.; Current opinion in pulmonary medicine
  • Low molecular weight heparins: a developmental perspective. Fareed, J.; Hoppensteadt, D.; Jeske, W.; Clarizio, R.; Walenga, J. M.; Expert opinion on investigational drugs
  • Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. Walenga, J. M.; Jeske, W. P.; Bara, L.; Samama, M. M.; Fareed, J.; Thrombosis research
  • Postburn edema and related changes in interleukin-2, leukocytes, platelet activation, endothelin-1, and C1 esterase inhibitor. Kowal-Vern, A.; Walenga, J. M.; Sharp-Pucci, M.; Hoppensteadt, D.; Gamelli, R. L.; The Journal of burn care & rehabilitation
  • Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Lewis, B. E.; Walenga, J. M.; Wallis, D. E.; Seminars in thrombosis and hemostasis
  • Efficacy of aprotinin with various anticoagulant agents in cardiopulmonary bypass. Terrell, M. R.; Walenga, J. M.; Koza, M. J.; Pifarré, R.; The Annals of thoracic surgery
  • Aprotinin modulation of platelet activation in patients undergoing cardiopulmonary bypass operations. Primack, C.; Walenga, J. M.; Koza, M. J.; Shankey, T. V.; Pifarre R; The Annals of thoracic surgery
  • Are the available low-molecular-weight heparin preparations the same? Fareed, J.; Jeske, W.; Hoppensteadt, D.; Clarizio, R.; Walenga, J. M.; Seminars in thrombosis and hemostasis
  • Successful treatment of heparin-associated thrombocytopenia and thrombosis using Hirulog. Chamberlin, J. R.; Lewis, B.; Leya, F.; Wallis, D.; Messmore, H.; Hoppensteadt, D.; Walenga, J. M.; Moran, S.; Fareed, J.; McKiernan, T.; The Canadian journal of cardiology
  • Comparative study on the use of anticoagulants heparin and recombinant hirudin in a rabbit traumatic anastomosis model. Fu, K.; Izquierdo, R.; Walenga, J. M.; Fareed, J.; Thrombosis research
  • Flow cytometric evaluation of platelet activation by ionic or nonionic contrast media and modulation by heparin and recombinant hirudin. Koza, M. J.; Shankey, T. C.; Walenga, J. M.; Moncada, R.; Fareed, J.; Pifarre, R.; Investigative radiology
  • TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. Hoppensteadt, D. A.; Walenga, J. M.; Fasanella, A.; Jeske, W.; Fareed, J.; Thrombosis research
  • Procoagulant and anticoagulant effects of intravascular contrast media as assessed by thromboelastography. Iqbal, O.; Jeske, W.; Hoppensteadt, D.; Koza, M.; Walenga, J. M.; Fareed, J.; Moncada, R.; Seminars in thrombosis and hemostasis
  • Thromboelastographic analysis of patients receiving aprotinin with comparisons to platelet aggregation and other assays. Koza, M. J.; Walenga, J. M.; Khenkina, Y. N.; Sullivan, H. J.; Montoya, A.; Pifarre, R.; Seminars in thrombosis and hemostasis
  • The approach of thromboelastography in the monitoring of new synthetic antithrombotic agents, GL-522 and GL-2021. Iqbal, O.; Jeske, W.; Hoppensteadt, D.; Walenga, J. M.; Fareed, J.; Seminars in thrombosis and hemostasis
  • Evaluation of hemostatic and fibrinolytic alterations associated with daily administration of low-molecular-weight heparin for a 12-week period. Lojewski, B.; Bacher, P.; Iqbal, O.; Walenga, J. M.; Hoppensteadt, D.; Leya, F.; Fareed, J.; Seminars in thrombosis and hemostasis
  • Impact of biotechnology in the diagnostic and therapeutic management of cardiovascular disorders. Fareed, J.; Hoppensteadt, D.; Iyer, L.; Koza, M.; Walenga, J. M.; Bermes, E.; Advances in experimental medicine and biology
  • Evaluation of CGP 39393 as the anticoagulant in cardiopulmonary bypass operation in a dog model. Walenga, J. M.; Koza, M. J.; Park, S. J.; Terrell, M. R.; Pifarré, R.; The Annals of thoracic surgery
  • Automation and quality control in the coagulation laboratory. Walenga, J. M.; Fareed, J.; Clinics in laboratory medicine
  • Current trends in the development of anticoagulant and antithrombotic drugs. Fareed, J.; Hoppensteadt, D.; Walenga, J. M.; Bick, R. L.; The Medical clinics of North America
  • Interleukin-2 and interleukin-6 in relation to burn wound size in the acute phase of thermal injury. Kowal-Vern, A.; Walenga, J. M.; Hoppensteadt, D.; Sharp-Pucci, M.; Gamelli, R. L.; Journal of the American College of Surgeons
  • Investigation of a thrombin inhibitor peptide as an alternative to heparin in cardiopulmonary bypass surgery. Chomiak, P. N.; Walenga, J. M.; Koza, M. J.; Reilly, T. M.; Turlapathy, P.; Pifarre, R.; Circulation
  • The antithrombotic and anticoagulant effects of a synthetic tripeptide and recombinant hirudin in various animal models. Bacher, P.; Walenga, J. M.; Iqbal, O.; Bajusz, S.; Breddin, K.; Fareed, J.; Thrombosis research
  • A simulated post-angioplasty low molecular weight heparin schedule in a non-human primate model. Bacher, P.; Iqbal, O.; Lojewski, B.; Walenga, J. M.; Leya, F.; Fareed, J.; Thrombosis research
  • Modulation of endothelial and platelet function by a polydeoxyribonucleotide derived drug "defibrotide". A dual mechanism in the control of vascular pathology. Bacher, P.; Kindel, G.; Walenga, J. M.; Fareed, J.; Thrombosis research
  • Evaluation of a low molecular weight heparin as an anticoagulant in a model of cardiopulmonary bypass surgery. Koza, M. J.; Messmore, H. L.; Wallock, M. E.; Walenga, J. M.; Pifarre, R.; Thrombosis research
  • Effects of aprotinin on anticoagulant monitoring: implications in cardiovascular surgery. Najman, D. M.; Walenga, J. M.; Fareed, J.; Pifarré, R.; The Annals of thoracic surgery
  • Heparan sulphate inhibition of cell proliferation induced by TGFbeta and PDGF. Silber, L. E.; Walenga, J. M.; Fareed, J.; Kovacs, E. J.; Mediators of inflammation
  • Postoperative monitoring of low molecular weight heparin prophylaxis in high-risk patients. Bacher, P.; Horst, B.; Breyer, H. G.; Hoppensteadt, D. A.; Walenga, J. M.; Fareed, J.; Seminars in thrombosis and hemostasis
  • Practical issues on the laboratory monitoring of low molecular weight heparins and related polysaccharides. Walenga, J. M.; Seminars in thrombosis and hemostasis
  • In vivo study of bleeding and antithrombotic effects of low molecular weight heparin ML-009723. Malinowska, K.; Iqbal, O.; Hoppensteadt, D. A.; Walenga, J. M.; Fareed, J.; Seminars in thrombosis and hemostasis
  • Evaluation of hematologic alterations associated with daily administration of low molecular weight heparin (Mono-Embolex) for a 12-week period. Lojewski, B.; Bacher, P.; Iqbal, O.; Walenga, J. M.; Hoppensteadt, D. A.; Leya, F.; Fareed, J.; Seminars in thrombosis and hemostasis
  • Biochemical and pharmacologic profile of low molecular weight heparin (LU 47311, Clivarin). Jeske, W.; Lojewski, B.; Walenga, J. M.; Hoppensteadt, D.; Ahsan, A.; Fareed, J.; Seminars in thrombosis and hemostasis
  • A comparison of the pharmacokinetic and pharmacodynamic profiles of Clexane and Lovenox in dogs. Iqbal, O.; Jeske, W.; Bacher, P.; Hoppensteadt, D. A.; Walenga, J. M.; Fareed, J.; Seminars in thrombosis and hemostasis
  • Current perspectives on low molecular weight heparins. Fareed, J.; Hoppensteadt, D. A.; Walenga, J. M.; Seminars in thrombosis and hemostasis
  • A new approach in monitoring recombinant hirudin during cardiopulmonary bypass. Koza, M. J.; Walenga, J. M.; Fareed, J.; Pifarre, R.; Seminars in thrombosis and hemostasis
  • Low molecular weight heparins. An objective overview. Hoppensteadt, D.; Walenga, J. M.; Fareed, J.; Drugs & aging
  • Tracheal and bronchial cartilaginous rings: warfarin sodium-induced calcification. Moncada, R. M.; Venta, L. A.; Venta, E. R.; Fareed, J.; Walenga, J. M.; Messmore, H. L.; Radiology
  • The effect of burn wound size on hemostasis: a correlation of the hemostatic changes to the clinical state. Kowal-Vern, A.; Gamelli, R. L.; Walenga, J. M.; Hoppensteadt, D.; Sharp-Pucci, M.; Schumacher, H. R.; The Journal of trauma
  • Pharmacological modulation of fibrinolysis by antithrombotic and cardiovascular drugs. Fareed, J.; Bacher, P.; Messmore, H. L.; Walenga, J. M.; Hoppensteadt, D. A.; Strano, A.; Pifarre, R.; Progress in cardiovascular diseases
  • Hemostatic abnormalities in total artificial heart patients as detected by specific blood markers. Walenga, J. M.; Hoppensteadt, D.; Fareed, J.; Pifarré, R.; The Annals of thoracic surgery
  • The thrombolytic potency of LMW-heparin compared to urokinase in a rabbit jugular vein clot lysis model. Bacher, P.; Welzel, D.; Iqbal, O.; Hoppensteadt, D.; Callas, D.; Walenga, J. M.; Fareed, J.; Thrombosis research
  • Some objective considerations for the use of heparins and recombinant hirudin in percutaneous transluminal coronary angioplasty. Fareed, J.; Walenga, J. M.; Leya, F.; Bacher, P.; Hoppensteadt, D.; Messmore, H.; Pifarre, R.; Seminars in thrombosis and hemostasis
  • Neutralization of recombinant hirudin: some practical considerations. Fareed, J.; Walenga, J. M.; Hoppensteadt, D.; Iyer, L.; Pifarre, R.; Seminars in thrombosis and hemostasis
  • Comparative studies on various assays for the laboratory evaluation of r-hirudin. Walenga, J. M.; Hoppensteadt, D.; Koza, M.; Pifarre, R.; Fareed, J.; Seminars in thrombosis and hemostasis
  • Potential use of recombinant hirudin as an anticoagulant in a cardiopulmonary bypass model. Walenga, J. M.; Bakhos, M.; Messmore, H. L.; Fareed, J.; Pifarre, R.; The Annals of thoracic surgery
  • An objective perspective on recombinant hirudin: a new anticoagulant and antithrombotic agent. Fareed, J.; Walenga, J. M.; Iyer, L.; Hoppensteadt, D.; Pifarre, R.; Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  • Comparison of recombinant hirudin and heparin as an anticoagulant in a cardiopulmonary bypass model. Walenga, J. M.; Bakhos, M.; Messmore, H. L.; Koza, M.; Wallock, M.; Orfei, E.; Fareed, J.; Pifarre, R.; Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  • Use of recombinant hirudin to increase the patency rate of microanastomosis in a rabbit model. Hubbard, T.; Olivier, T.; Bacher, P.; Walenga, J. M.; Galal, H.; Fareed, J.; Pifarre, R.; Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  • Effect of dermatan sulfate and heparan sulfate on platelet activity compared to heparin. Hoppensteadt, D. A.; Walenga, J. M.; Fareed, J.; Seminars in thrombosis and hemostasis
  • Molecular and functional heterogeneity in dermatan sulfate preparations. Fareed, J.; Hoppensteadt, D.; Walenga, J. M.; Ahsan, A.; Coyne, E.; Breddin, H. K.; Seminars in thrombosis and hemostasis
  • Protamine sulfate neutralization of lactobionic acid amides. Hoppensteadt, D.; Walenga, J. M.; Fareed, J.; Seminars in thrombosis and hemostasis
  • Pharmacodynamics of a sulfated lactobionic acid amide-derived antithrombotic agent (Aprosulate) in primates. Fareed, J.; Coker, S.; Iqbal, O.; Hoppensteadt, D.; Walenga, J. M.; Seminars in thrombosis and hemostasis
  • Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudin. Fareed, J.; Walenga, J. M.; Pifarre, R.; Hoppensteadt, D.; Koza, M.; Haemostasis
  • Laboratory assays for the evaluation of recombinant hirudin. Walenga, J. M.; Hoppensteadt, D.; Koza, M.; Wallock, M.; Pifarre, R.; Fareed, J.; Haemostasis
  • Non-heparin glycosaminoglycan-derived drugs: a biochemical and pharmacologic perspective. Walenga, J. M.; Hoppensteadt, D.; Fareed, J.; Seminars in thrombosis and hemostasis
  • Behavioral, endocrine, and neurochemical effects of sulfomucopolysaccharide treatment in the aged Fischer 344 male rat. Lorens, S. A.; Guschwan, M.; Hata, N.; van de Kar, L. D.; Walenga, J. M.; Fareed, J.; Seminars in thrombosis and hemostasis
  • Experimental and clinical validation of the prophylactic antithrombotic effects of a low molecular weight heparin (enoxaparin). Fareed, J.; Walenga, J. M.; Hoppensteadt, D.; Borris, L. C.; Lassen, M. R.; Seminars in thrombosis and hemostasis
  • Laboratory monitoring of the clinical effects of low molecular weight heparins. Walenga, J. M.; Hoppensteadt, D.; Fareed, J.; Thrombosis research. Supplement
  • Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin. Hoppensteadt, D.; Walenga, J. M.; Fareed, J.; Thrombosis research
  • Global and molecular hemostatic markers in acute myeloid leukemia. Reddy, V. B.; Kowal-Vern, A.; Hoppensteadt, D. A.; Kumar, A.; Walenga, J. M.; Fareed, J.; Schumacher, H. R.; American journal of clinical pathology
  • Thrombogenic potential of nonionic contrast media? Fareed, J.; Walenga, J. M.; Saravia, G. E.; Moncada, R. M.; Radiology
  • Pharmacologic profile of a low molecular weight heparin (enoxaparin): experimental and clinical validation of the prophylactic antithrombotic effects. Fareed, J.; Walenga, J. M.; Lassen, M.; Borris, L.; Hoppensteadt, D.; Murphy, R.; Ahsan, A.; Weber, S.; Jorgensen, L. N.; Hauch, O.; Acta chirurgica Scandinavica. Supplementum
  • Chemical and biological heterogeneity in low molecular weight heparins: implications for clinical use and standardization. Fareed, J.; Walenga, J. M.; Hoppensteadt, D.; Racanelli, A.; Coyne, E.; Seminars in thrombosis and hemostasis
  • Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate, and heparin. Hoppensteadt, D.; Racanelli, A.; Walenga, J. M.; Fareed, J.; Seminars in thrombosis and hemostasis
  • Development of recombinant hirudin as a therapeutic anticoagulant and antithrombotic agent: some objective considerations. Walenga, J. M.; Pifarre, R.; Hoppensteadt, D. A.; Fareed, J.; Seminars in thrombosis and hemostasis
  • Antithrombotic drugs in pelvic surgery. Fareed, J.; Walenga, J. M.; Cornelli, U.; Seminars in thrombosis and hemostasis
  • Biochemical and pharmacologic inequivalence of low molecular weight heparins. Fareed, J.; Walenga, J. M.; Hoppensteadt, D.; Huan, X.; Nonn, R.; Annals of the New York Academy of Sciences
  • Importance of a 3-O-sulfate group in a heparin pentasaccharide for antithrombotic activity. Walenga, J. M.; Petitou, M.; Samama, M.; Fareed, J.; Choay, J.; Thrombosis research
  • Aggregates in heparin. Coyne, E.; Walenga, J. M.; Fareed, J.; Journal of pharmaceutical sciences
  • The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity. Walenga, J. M.; Bara, L.; Petitou, M.; Samama, M.; Fareed, J.; Choay, J.; Thrombosis research
  • Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparins. Fareed, J.; Walenga, J. M.; Racanelli, A.; Hoppensteadt, D.; Huan, X.; Messmore, H. L.; Haemostasis
  • Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins. Fareed, J.; Walenga, J. M.; Hoppensteadt, D.; Huan, X.; Racanelli, A.; Haemostasis
  • Pharmacologic profiling of defibrotide in experimental models. Fareed, J.; Walenga, J. M.; Hoppensteadt, D. A.; Kumar, A.; Ulutin, O. N.; Cornelli, U.; Seminars in thrombosis and hemostasis
888-584-7888

Dismiss Modal

Close 

Where would you like to share?